Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-CLAM for Relapsed/Refractory AML
NCT04196010Phase 1Terminated
- Sponsor
- University of Washington
- Start
- May 2020
- Primary completion
- Oct 2021
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cladribine, cytarabine and mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML) and myeloid neoplasm, sponsored by University of Washington. Primary endpoint: Maximum Tolerated Dose at 35 days. Started May 2020; status: terminated.
02
Drugs
cladribinecytarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)myeloid neoplasm
Beyond the preview
Go deeper on NCT04196010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196010.